SCDC Publications

CDC scientific articles

2024

Emergency department utilization before and during the COVID-19 pandemic among individuals with sickle cell disease. Attell BK, Plaxco AP, Zhou M, Valle J, Reeves SL, Patel PN, Latta K, Smeltzer MP, Snyder AB. BMC Emerg Med. 2024 Jul 29;24(1):134. doi: 10.1186/s12873-024-01043-5. PMID: 39075379; PMCID: PMC11287848.

Examining community-level social vulnerability and emergency department use for people living with sickle cell disease in Michigan. Swallow J, Latta K, Plegue M, Peng HK, Tipirneni R, Smith D, Lê-Scherban F, Dombkowski KJ, Reeves SL. Pediatr Blood Cancer. 2024;e31225. doi: 10.1002/pbc.31225. Epub ahead of print. PMID: 39054678.

Prevalence, mortality, and access to care for chronic kidney disease in Medicaid-enrolled adults with sickle cell disease in California: Retrospective cohort study. Valle J, Lebensburger JD, Garimella PS, Gopal S. JMIR Public Health Surveill. 2024;10:e57290. doi:10.2196/57290.

Emergency department 30-day emergency department revisits among people with sickle cell disease: variations in characteristics. Rushing M, Horiuchi S, Zhou M, Kavanagh PL, Reeves SL, Snyder A, Paulukonis S. Pediatr Blood Cancer. 2024;e31188. doi:10.1002/pbc.31188.

Medicaid coverage in early childhood for children with sickle cell disease. Horiuchi SS, Reeves SL, Plaxco AP, Peng HK, Zhou M, Kayle M, Hulihan M. JAMA Netw Open. 2024;7(7):e2421491. doi:10.1001/jamanetworkopen.2024.21491.

Acute care utilization among individuals with sickle cell disease and related cardiopulmonary and renal complications.
Singh A, Brousseau DC, Dasgupta M, Shet AS, Field JJ, Brandow AM. PLoS One. 2024 Apr 16;19(4):e0297469. doi: 10.1371/journal.pone.0297469. PMID: 38626063; PMCID: PMC11020686.

Assessing patterns of telehealth use among people with sickle cell disease enrolled in Medicaid during the start of the COVID-19 pandemic.
Reeves SL, Plegue M, Patel PN, Paulukonis ST, Horiuchi SS, Zhou M, Attell BK, Pace BS, Snyder AB, Plaxco AP, Mukhopadhyay A, Smeltzer MP, Ellimootil CS, Hulihan M. Telemed J E Health. 2024 Apr 11. doi: 10.1089/tmj.2023.0422. Epub ahead of print. PMID: 38603584.

Birth Prevalence of Sickle Cell Disease and County-Level Social Vulnerability — Sickle Cell Data Collection Program, 11 States, 2016–2020.
Kayle M, Blewer AL, Pan W, et al. MMWR Morb Mortal Wkly Rep 2024;73:248–254. DOI: http://dx.doi.org/10.15585/mmwr.mm7312a1.

2023

Increasing visibility of sickle cell disease in Indiana: Establishing baseline prevalence using integrated data from multiple sources.
Okolo AI, Jacob SA, Dixon BE, Valvi NR, Janson IA, Hardesty BR. Public Health Rep. 2023 May 26;333549231170229. doi: 10.1177/00333549231170229.

COVID-19 infection and outcomes in newborn screening cohorts of sickle cell trait and sickle cell disease in Michigan and Georgia.
Paulukonis ST, Snyder A, Smeltzer MP, Sutaria AN, Hurden I, Latta K, Chennuri S, Vichinsky E, Reeves SL. J Pediatr Hematol Oncol. 2023 May 1;45(4):174-180. doi: 10.1097/MPH.0000000000002671. Epub 2023 Mar 20.

Case ascertainment of sickle cell disease using surveillance or single administrative database case definitions.
Reeves SL, Horiuchi S, Zhou M, Paulukonis S, Snyder A, Wilson-Frederick S, Hulihan M. Public Health Rep. 2023 May 19;333549231166465. doi: 10.1177/00333549231166465.

Evaluating the discriminatory ability of the Sickle Cell Data Collection program's administrative claims case definition in identifying adults with sickle cell disease: Validation study.
Singh A, Sontag MK, Zhou M, Dasgupta M, Crume T, McLemore M, Galadanci N, Randall E, Steiner N, Brandow AM, Koch K, Field JJ, Hassell K, Snyder AB, Kanter J. JMIR Public Health Surveill. 2023 Jun 28;9:e42816. doi: 10.2196/42816.

Common data model for sickle cell disease surveillance: considerations and implications.
Smeltzer MP, Reeves SL, Cooper WO, Attell BK, Strouse JJ, Takemoto CM, Kanter J, Latta K, Plaxco AP, Davis RL, Hatch D, Reyes C, Dombkowski K, Snyder A, Paulukonis S, Singh A, Kayle M. JAMIA Open. 2023 May 27;6(2):ooad036. doi: 10.1093/jamiaopen/ooad036.

2022

Trends in blood transfusion, hydroxyurea use, and iron overload among children with sickle cell disease enrolled in Medicaid, 2004–2019.
Tang AY, Zhou M, Maillis AN, Lai KW, Lane PA, Snyder AB. Pediatr Blood Cancer. 2023 Mar;70(3):e30152. doi: 10.1002/pbc.30152. Epub 2022 Dec 29. PMID: 36579749.

Sickle cell disease among Latinx in California.
Valle J, Baker JR, Madrigal D, Ferrerosa J, Paulukonis S. PLoS One. 2022 Oct 27;17(10):e0276653. doi: 10.1371/journal.pone.0276653.

Hematologist encounters among Medicaid patients who have sickle cell disease.
Horiuchi SS, Zhou M, Snyder A, Paulukonis ST. Blood Adv. 2022 Sep 13;6(17):5128-5131. doi: 10.1182/bloodadvances.2022007622.

Improving outcomes for patients with sickle cell disease in the United States: Making the case for more resources, surveillance, and longitudinal data.
Kanter J, Meier ER, Hankins JS, Paulukonis ST, Snyder AB. JAMA Health Forum. 2021 Oct 1;2(10):e213467. doi: 10.1001/jamahealthforum.2021.3467.

Surveillance for sickle cell disease — Sickle Cell Data Collection program, two states, 2004–2018.
Snyder AB, Lakshmanan S, Hulihan MM, Paulukonis ST, Zhou M, Horiuchi SS, Abe K, Pope SN, Schieve LA. MMWR Surveill Summ. 2022 Oct 7;71(9):1-18. doi: 10.15585/mmwr.ss7109a1.

Too few children, teens with sickle cell anemia receive screening, medication to prevent serious complications.
Stephenson, J. JAMA Health Forum. 2022 Nov 4;3(11):e224780. doi: 10.1001/jamahealthforum.2022.4780.

2021

Hydroxyurea use after transitions of care among young adults with sickle cell disease and Tennessee Medicaid insurance.
Mathias JG, Nolan VG, Klesges LM, Badawy SM, Cooper WO, Hankins JS, Smeltzer MP. JAMA Netw Open. 2021 Oct 1;4(10):e2128971. doi: 10.1001/jamanetworkopen.2021.28971. PMID: 34643722.

Concurrent use of hydroxyurea and deferasirox in Californians with sickle cell disease.
Wong TE, Valle J, Paulukonis S. Health Sci Rep. 2021;4:e323. doi: 10.1002/hsr2.323.

2020

Using surveillance to determine the number of individuals with sickle cell disease in California and Georgia, 2005-2016 [published online ahead of print, 2020 Aug 12].
Aluc A, Zhou M, Paulukonis ST, Snyder AB, Wong D, Hulihan MM. Pediatr Hematol Oncol. 2020;1-5. doi:10.1080/08880018.2020.1779886.

Acute care utilization at end of life in sickle cell disease: Highlighting the need for a palliative approach.
Johnston EE, Adesina OO, Alvarez E, Amato H, Paulukonis S, Nichols A, Chamberlain LJ, Bhatia S. J Palliat Med. 2020 Jan;23(1):24-32.

Impact of Medicaid expansion on access and healthcare among individuals with sickle cell disease.
Kayle M, Valle J, Paulukonis S, Holl JL, Tanabe P, French DD, Garg R, Liem RI, Badawy SM, Treadwell MJ. Pediatr Blood Cancer. 2020 May;67(5):e28152.

2019

Improving an administrative case definition for longitudinal surveillance of sickle cell disease.
Snyder AB, Zhou M, Theodore R, Quarmyne MO, Eckman J, Lane PA. Public Health Rep. 2019 May/Jun;134(3):274-281. doi: 10.1177/0033354919839072.

Characterizing complication risk from multisite, intermittent transfusions for the treatment of sickle cell disease.
Tang A, Branscomb J, Zhou M, Snyder A, Eckman J. Pediatr Blood Cancer. 2019 Oct;66(10):e27921.

2018

SCDC Program Report: Data to Action

2017

CDC Grand Rounds: Improving the lives of persons with sickle cell disease.
Hulihan M, Hassell KL, Raphael JL, Smith-Whitley K, Thorpe P. MMWR Morb Mortal Wkly Rep. 2017; 66:1269–1271.

Emergency department utilization by Californians with sickle cell disease, 2005–2014.
Paulukonis ST, Feuchtbaum LB, Coates TD, Neumayr LD, Treadwell MJ, Vichinsky EP, Hulihan MM. Pediatr Blood Cancer. 2017 Jun; 64(6).

The accuracy of hospital ICD-9-CM codes for determining sickle cell disease genotype.
Snyder AB, Lane PA, Zhou M, Paulukonis ST, Hulihan MM. J Rare Dis Res Treat. 2017; 2(4):39–45.